ELR+ CXC Chemokines and their Role in Malignancy
- Authors: Ellen C. Keeley1, Borna Mehrad2, Robert M. Strieter3
-
View Affiliations Hide Affiliations1 Department of Medicine, Divisions of Cardiology, Universityof Virginia, Charlottesville, Virginia, USA 2 Pulmonary and Critical Care Medicine, Universityof Virginia, Charlottesville, Virginia, USA 3 Pulmonary and Critical Care Medicine, Universityof Virginia, Charlottesville, Virginia, USA
- Source: The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis , pp 81-87
- Publication Date: June 2012
- Language: English
ELR+ CXC Chemokines and their Role in Malignancy, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781608052561/chapter-5-1.gif
The tumor microenvironment is extremely complex and depends on tumor cell interaction with the responding host cells. Angiogenesis, or new blood vessel growth from pre-existing vasculature, is a preeminent feature of successful tumor growth of all solid tumors. While a number of factors produced by both the tumor cells and host responding cells have been discovered that promote tumorassociated angiogenesis, increasing evidence is growing to support the important role of CXC chemokines in this process. As a family of cytokines, the CXC chemokines are pleiotropic in their ability to regulate tumor-associated angiogenesis. In this chapter we will focus on the ELR+ CXC chemokines and their contribution to tumor-associated angiogenesis.
-
From This Site
/content/books/9781608052561.chapter-5dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
